rabbit polyclonal anti cxcl8  (Novus Biologicals)

Journal: Drug Design, Development and Therapy

Article Title: Molecular Mechanism Underlying Effects of Wumeiwan on Steroid-Dependent Asthma: A Network Pharmacology, Molecular Docking, and Experimental Verification Study

doi: 10.2147/DDDT.S349950

Figure Lengend Snippet: Screening of HUB genes. ( A ) PPI network of WMW against SDA performed by STRING database with the parameters of the organism for “ Homo sapiens ” and the minimum required interaction score≥ 0.9. ( B ) 35 HUB genes network performed by Cytoscape yFiles Radial Layout. Low degree values showed large sizes and bright colors, and small sizes and dark colors for high degree values on the contrary. ( C ) The 10 core targets network, including JUN, MAPK1, IL6, TP53, RELA, HSP90AA1, EGFR, AKT1, CXCL8 , and TNF.

Article Snippet: Rabbit Anti-IL-8/CXCL8 antibody was purchased from Bioss Antibodies (Beijing, China)[bs-0780R].

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: Molecular Mechanism Underlying Effects of Wumeiwan on Steroid-Dependent Asthma: A Network Pharmacology, Molecular Docking, and Experimental Verification Study

doi: 10.2147/DDDT.S349950

Figure Lengend Snippet: DC, BC, CC, and Stress Information of HUB Genes

Article Snippet: Rabbit Anti-IL-8/CXCL8 antibody was purchased from Bioss Antibodies (Beijing, China)[bs-0780R].

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: Molecular Mechanism Underlying Effects of Wumeiwan on Steroid-Dependent Asthma: A Network Pharmacology, Molecular Docking, and Experimental Verification Study

doi: 10.2147/DDDT.S349950

Figure Lengend Snippet: Molecular Docking Results

Article Snippet: Rabbit Anti-IL-8/CXCL8 antibody was purchased from Bioss Antibodies (Beijing, China)[bs-0780R].

Techniques: Binding Assay

Journal: Drug Design, Development and Therapy

Article Title: Molecular Mechanism Underlying Effects of Wumeiwan on Steroid-Dependent Asthma: A Network Pharmacology, Molecular Docking, and Experimental Verification Study

doi: 10.2147/DDDT.S349950

Figure Lengend Snippet: Molecular docking between CXCL8 and five pivotal ingredients, including quercetin ( A ), beta-sitosterol ( B ), kaempferol ( C ), palmidin A ( D ), and candletoxin A ( E ).

Article Snippet: Rabbit Anti-IL-8/CXCL8 antibody was purchased from Bioss Antibodies (Beijing, China)[bs-0780R].

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: Molecular Mechanism Underlying Effects of Wumeiwan on Steroid-Dependent Asthma: A Network Pharmacology, Molecular Docking, and Experimental Verification Study

doi: 10.2147/DDDT.S349950

Figure Lengend Snippet: Correlation heatmap of docking results between the 10 core targets and five pivotal ingredients. The binding energy was marked by different colors, red for higher scores and green for lower scores. It could be observed that all core targets could stably bind with five pivotal ingredients, especially CXCL8 showed the lowest energy.

Article Snippet: Rabbit Anti-IL-8/CXCL8 antibody was purchased from Bioss Antibodies (Beijing, China)[bs-0780R].

Techniques: Binding Assay, Stable Transfection

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Flow chart representing the recruitment of LTx patients for analysis of the neutrophil phenotype (cohort 1) and CXCL8 proteoforms (cohort 2). ( A ) To study the neutrophil phenotype, a first cohort of 100 fresh BAL fluid and 50 peripheral blood samples were collected from 134 individual patients, including 16 patients with a paired BAL fluid and peripheral blood sample. BAL fluid samples were excluded for flow cytometry analysis if cell counts were insufficient or upon severe blood contamination. Samples with insufficient neutrophils for proper flow cytometry analysis were excluded as well. Other reasons for exclusion were samples derived from patients on post-operative day 1 or upon hospital discharge immediately after transplantation, from patients with other severe complications (anastomotic stricture, pulmonary embolisms) or without clear diagnosis. Samples were categorized retrospectively to be derived from LTx patients with CLAD or pulmonary infection or stable LTx recipients according to clinical guidelines (see section). ( B ) To study CXCL8 proteoforms in LTx, COVID-19 and influenza patients, -80 °C-stored BAL fluid supernatants from a second cohort of 55 individual patients were used

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Flow Cytometry, Derivative Assay, Transplantation Assay, Biomarker Discovery, Infection

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Clinical characteristics CXCL8 proteoform cohort

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Infection, Biomarker Discovery, Cell Counting

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Detection of endogenous CXCL8 proteoforms in BAL fluid. ( A - C ) Neutrophil counts and CXCL8 levels in BAL fluid samples from CLAD ( n = 12), infected ( n = 6) and stable LTx patients ( n = 6) used for CXCL8 proteoform characterization. ( D , E ) Endogenous CXCL8 proteoforms were determined by ISTAMPA in the BAL fluid supernatants of LTx patients with CLAD or infection. Total CXCL8 levels were below the detection limit for ISTAMPA analysis in stable LTx recipients. CXCL8 proteoforms were presented according to their relative abundance in the BAL fluids, expressed as percentage of total CXCL8. ( F , G ) Correlation between the relative abundance of the most potent proteoform CXCL8(9–77) and the percentage and absolute numbers of neutrophils in the LTx BAL fluid samples (CLAD and infection combined). ( H , I ) ISTAMPA analysis of endogenous CXCL8 proteoforms in COVID-19 ( n = 24) and influenza ( n = 7) BAL fluid supernatants. Data are shown as box-and-whisker plots (box: median with interquartile range, whiskers: full data distribution), with each dot representing an individual BAL fluid sample, and statistically analyzed by Kruskal-Wallis tests with Dunn’s multiple comparisons tests: * p < 0.05; ** p < 0.01; *** p < 0.001. Correlation analysis was performed calculating a Spearman correlation coefficient and plotted utilizing a simple linear regression line

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Infection, Whisker Assay

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Proteolytic processing of intact CXCL8 in BAL fluid. ( A ) Recombinant human CXCL8(1–77) [125 ng] was spiked in 10 µL of BAL fluid supernatant from CLAD ( n = 12), infected ( n = 6) or stable LTx patients ( n = 6) and from patients with COVID-19 ( n = 10) or influenza ( n = 7). After incubation for 3 h at 37 °C, CXCL8 proteolysis was analyzed by ISTAMPA. ( B ) CXCL8 proteoforms were also determined immediately after spiking CXCL8 [without 37 °C incubation but including the required 30 min pre-purification of the CXCL8 proteoforms at room temperature (RT) as part of the ISTAMPA procedure] and after 16 h of incubation at 37 °C in the COVID-19 BAL fluids. CXCL8 proteoforms were presented according to their relative abundance in the BAL fluids, expressed as percentage of total CXCL8. ( C , D ) Correlation between the relative abundance of the intact CXCL8(1–77) or the truncated CXCL8(6–77) proteoform after 3 h incubation at 37 °C and the elastinolytic activity in the COVID-19 BAL fluid samples . Data are shown as box-and-whisker plots (box: median with interquartile range, whiskers: full data distribution), with each dot representing an individual BAL fluid sample, and statistically analyzed by Kruskal-Wallis tests with Dunn’s multiple comparisons tests: * p < 0.05; **** p < 0.0001. Correlation analysis was performed calculating a Spearman correlation coefficient and plotted utilizing a simple linear regression line

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Recombinant, Infection, Incubation, Purification, Activity Assay, Whisker Assay

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Inhibition of proteolytic processing of CXCL8 in BAL fluid. ( A ) Recombinant human CXCL8(6–77) [125 ng] was spiked in 10 µL of BAL fluid supernatant ( n = 3–6) from COVID-19 (indicated by dots) and CLAD patients (indicated by triangles) and incubated for 3 h at 37 °C, in the absence or presence of the metalloprotease inhibitor EDTA. ( B ) Recombinant human CXCL8(1–77) [125 ng] was spiked in 10 µL of BAL fluid supernatant ( n = 8–9) from COVID-19 (dots) and CLAD patients (triangles) and incubated for 3 h at 37 °C, in the absence or presence of the serine protease inhibitor AEBSF or/and the metalloprotease inhibitor EDTA. After incubation, CXCL8 proteolysis was determined by ISTAMPA. All CXCL8 proteoforms were presented according to their relative abundance in the sample, expressed as percentage of total CXCL8. Data are shown as box-and-whisker plots (box: median with interquartile range, whiskers: full data distribution), with each dot representing an individual BAL fluid sample, and statistically analyzed by Mann-Whitney U tests or Kruskal-Wallis tests with Dunn’s multiple comparisons tests: * p < 0.05; *** p < 0.001; **** p < 0.0001

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Inhibition, Recombinant, Incubation, Protease Inhibitor, Whisker Assay, MANN-WHITNEY

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Flow chart representing the recruitment of LTx patients for analysis of the neutrophil phenotype (cohort 1) and CXCL8 proteoforms (cohort 2). ( A ) To study the neutrophil phenotype, a first cohort of 100 fresh BAL fluid and 50 peripheral blood samples were collected from 134 individual patients, including 16 patients with a paired BAL fluid and peripheral blood sample. BAL fluid samples were excluded for flow cytometry analysis if cell counts were insufficient or upon severe blood contamination. Samples with insufficient neutrophils for proper flow cytometry analysis were excluded as well. Other reasons for exclusion were samples derived from patients on post-operative day 1 or upon hospital discharge immediately after transplantation, from patients with other severe complications (anastomotic stricture, pulmonary embolisms) or without clear diagnosis. Samples were categorized retrospectively to be derived from LTx patients with CLAD or pulmonary infection or stable LTx recipients according to clinical guidelines (see section). ( B ) To study CXCL8 proteoforms in LTx, COVID-19 and influenza patients, -80 °C-stored BAL fluid supernatants from a second cohort of 55 individual patients were used

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Flow Cytometry, Derivative Assay, Transplantation Assay, Biomarker Discovery, Infection

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Clinical characteristics CXCL8 proteoform cohort

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Infection, Biomarker Discovery, Cell Counting

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Detection of endogenous CXCL8 proteoforms in BAL fluid. ( A - C ) Neutrophil counts and CXCL8 levels in BAL fluid samples from CLAD ( n = 12), infected ( n = 6) and stable LTx patients ( n = 6) used for CXCL8 proteoform characterization. ( D , E ) Endogenous CXCL8 proteoforms were determined by ISTAMPA in the BAL fluid supernatants of LTx patients with CLAD or infection. Total CXCL8 levels were below the detection limit for ISTAMPA analysis in stable LTx recipients. CXCL8 proteoforms were presented according to their relative abundance in the BAL fluids, expressed as percentage of total CXCL8. ( F , G ) Correlation between the relative abundance of the most potent proteoform CXCL8(9–77) and the percentage and absolute numbers of neutrophils in the LTx BAL fluid samples (CLAD and infection combined). ( H , I ) ISTAMPA analysis of endogenous CXCL8 proteoforms in COVID-19 ( n = 24) and influenza ( n = 7) BAL fluid supernatants. Data are shown as box-and-whisker plots (box: median with interquartile range, whiskers: full data distribution), with each dot representing an individual BAL fluid sample, and statistically analyzed by Kruskal-Wallis tests with Dunn’s multiple comparisons tests: * p < 0.05; ** p < 0.01; *** p < 0.001. Correlation analysis was performed calculating a Spearman correlation coefficient and plotted utilizing a simple linear regression line

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Infection, Whisker Assay

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Proteolytic processing of intact CXCL8 in BAL fluid. ( A ) Recombinant human CXCL8(1–77) [125 ng] was spiked in 10 µL of BAL fluid supernatant from CLAD ( n = 12), infected ( n = 6) or stable LTx patients ( n = 6) and from patients with COVID-19 ( n = 10) or influenza ( n = 7). After incubation for 3 h at 37 °C, CXCL8 proteolysis was analyzed by ISTAMPA. ( B ) CXCL8 proteoforms were also determined immediately after spiking CXCL8 [without 37 °C incubation but including the required 30 min pre-purification of the CXCL8 proteoforms at room temperature (RT) as part of the ISTAMPA procedure] and after 16 h of incubation at 37 °C in the COVID-19 BAL fluids. CXCL8 proteoforms were presented according to their relative abundance in the BAL fluids, expressed as percentage of total CXCL8. ( C , D ) Correlation between the relative abundance of the intact CXCL8(1–77) or the truncated CXCL8(6–77) proteoform after 3 h incubation at 37 °C and the elastinolytic activity in the COVID-19 BAL fluid samples . Data are shown as box-and-whisker plots (box: median with interquartile range, whiskers: full data distribution), with each dot representing an individual BAL fluid sample, and statistically analyzed by Kruskal-Wallis tests with Dunn’s multiple comparisons tests: * p < 0.05; **** p < 0.0001. Correlation analysis was performed calculating a Spearman correlation coefficient and plotted utilizing a simple linear regression line

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Recombinant, Infection, Incubation, Purification, Activity Assay, Whisker Assay

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs

doi: 10.1007/s00018-024-05500-z

Figure Lengend Snippet: Inhibition of proteolytic processing of CXCL8 in BAL fluid. ( A ) Recombinant human CXCL8(6–77) [125 ng] was spiked in 10 µL of BAL fluid supernatant ( n = 3–6) from COVID-19 (indicated by dots) and CLAD patients (indicated by triangles) and incubated for 3 h at 37 °C, in the absence or presence of the metalloprotease inhibitor EDTA. ( B ) Recombinant human CXCL8(1–77) [125 ng] was spiked in 10 µL of BAL fluid supernatant ( n = 8–9) from COVID-19 (dots) and CLAD patients (triangles) and incubated for 3 h at 37 °C, in the absence or presence of the serine protease inhibitor AEBSF or/and the metalloprotease inhibitor EDTA. After incubation, CXCL8 proteolysis was determined by ISTAMPA. All CXCL8 proteoforms were presented according to their relative abundance in the sample, expressed as percentage of total CXCL8. Data are shown as box-and-whisker plots (box: median with interquartile range, whiskers: full data distribution), with each dot representing an individual BAL fluid sample, and statistically analyzed by Mann-Whitney U tests or Kruskal-Wallis tests with Dunn’s multiple comparisons tests: * p < 0.05; *** p < 0.001; **** p < 0.0001

Article Snippet: Total CXCL8 concentrations were determined using a specific sandwich ELISA: 0.5 μg/mL polyclonal rabbit anti-human CXCL8 (#500-P28; PeproTech, Cranbury, NJ, USA) and 0.2 μg/mL biotinylated polyclonal rabbit anti-human CXCL8 antibodies (#500-P28BT; PeproTech) with HRP-conjugated streptavidin (R&D Systems, Minneapolis, MN, USA) were used for coating and detection, respectively.

Techniques: Inhibition, Recombinant, Incubation, Protease Inhibitor, Whisker Assay, MANN-WHITNEY

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Workflow for immunosorbent tandem mass spectrometry proteoform analysis (ISTAMPA). (1) Synovial fluids are collected from the inflamed joints of patients with arthritis. (2) Total CXCL8 is extracted from patient samples by immunosorbent purification using antibody-coupled magnetic beads. (3) Isolated CXCL8 proteoforms are subjected to analysis by nano-UPLC-MS/MS. (4, 5) The detection and quantification of signature fragment ions, generated by top-down collision-induced dissociation (CID) of a pre-selected precursor ion, at the expected elution time point, strongly indicates the presence of a specific CXCL8 proteoform. In general, truncated CXCL8 proteoforms display an enhanced capacity to induce neutrophil migration and activation. This figure is created with BioRender software.

Article Snippet: After three washing steps, captured CXCL8 forms were detected using biotinylated polyclonal rabbit anti-human CXCL8 (500-P28BT; PeproTech, Rocky Hill, NJ), raised against recombinant human CXCL8(6-77), combined with peroxidase-conjugated streptavidine (R&D Systems, Minneapolis, MN).

Techniques: Mass Spectrometry, Purification, Magnetic Beads, Isolation, Tandem Mass Spectroscopy, Generated, Migration, Activation Assay, Software

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Detection of CXCL8 proteoforms by top-down tandem mass spectrometry. (A) Parameters are optimized to ensure that only the acid-labile Asp-Pro (DP) bond breaks during low-energy fragmentation and only two fragment ions are generated. (B) Mass spectra (single MS) showing the intensity of multiple charged ions of CXCL8(1-77), CXCL8(6-77) and CXCL8(9-77) as a function of their m/z values. Ions with m/z values of 892.8 [for CXCL8(1-77)], 932.3 [for CXCL8(6-77)] or 900.4 [for CXCL8(9-77)] were isolated and fragmented with low energy CID. The resulting fragmentation spectra are shown in the lower panels in (C) . Diamonds indicate the m/z value of the precursor ions selected for fragmentation. Extracted ion chromatograms (EIC) (top panels) show the detection of m/z values (±0.5) of the two signature fragment ions during protein elution. Relative quantification of CXCL8 forms is performed based on the intensity of the two major fragment ions in the EIC. (D) Dose-response curves for the simultaneous quantification of three CXCL8 forms in MRM mode (amounts ranging from 3.1 pg to 12.5 ng). Regression analysis was performed to fit curves to data. Results are represented as mean ± SEM ( n ≥ 4).

Article Snippet: After three washing steps, captured CXCL8 forms were detected using biotinylated polyclonal rabbit anti-human CXCL8 (500-P28BT; PeproTech, Rocky Hill, NJ), raised against recombinant human CXCL8(6-77), combined with peroxidase-conjugated streptavidine (R&D Systems, Minneapolis, MN).

Techniques: Mass Spectrometry, Generated, Isolation, Quantitative Proteomics

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Site-specific fragmentation of CXCL8 proteoform ions by top-down ion trap tandem mass spectrometry at limited fragmentation energy.

Article Snippet: After three washing steps, captured CXCL8 forms were detected using biotinylated polyclonal rabbit anti-human CXCL8 (500-P28BT; PeproTech, Rocky Hill, NJ), raised against recombinant human CXCL8(6-77), combined with peroxidase-conjugated streptavidine (R&D Systems, Minneapolis, MN).

Techniques: Mass Spectrometry, Sequencing

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Detection of CXCL8 proteoforms in cell culture supernatant from osteosarcoma cells. The MG-63 osteosarcoma cell line was stimulated with the synthetic double stranded RNA poly rI:rC to produce CXCL8. Partially purified cell culture supernatant was subjected to top-down nano-LC-MS/MS analysis. Two nano-LC-MS/MS runs were performed to examine the presence and quantity of eight CXCL8 proteoforms in MRM mode. (A) Extracted ion chromatograms (EIC) showing the intensity of m/z values of signature fragment ions (±0.5) generated by fragmentation of a specific precursor ion (indicated between brackets) during protein elution. (B) Fragmentation spectra confirming the presence of signature ions of CXCL8(-2-77), CXCL8(1-77), CXCL8(3-77), CXCL8(6-77), CXCL8(7-77) and CXCL8(8-77). (C) Relative abundance of the detected CXCL8 proteoforms.

Article Snippet: After three washing steps, captured CXCL8 forms were detected using biotinylated polyclonal rabbit anti-human CXCL8 (500-P28BT; PeproTech, Rocky Hill, NJ), raised against recombinant human CXCL8(6-77), combined with peroxidase-conjugated streptavidine (R&D Systems, Minneapolis, MN).

Techniques: Cell Culture, Purification, Liquid Chromatography with Mass Spectroscopy, Generated

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Detection of CXCL8 by top down-tandem mass spectrometry proves proteolytic activation in synovial fluids of arthritis patients. Total CXCL8 was extracted from synovial fluids of RA ( n = 14) and JIA patients ( n = 12) by immunosorbent isolation and subjected to nano-LC-MS/MS analysis. For each sample, two top-down nano-LC-MS/MS runs were performed to examine the presence of eight CXCL8 forms in MRM mode. (A) Extracted ion chromatograms (EIC) show the intensity of m/z values of signature fragment ions (±0.5) generated by fragmentation of a specific precursor ion (indicated between brackets) during protein elution. A representative experiment is shown (RA patient). (B) Representative fragmentation spectra confirm the presence of signature ions of CXCL8(1-77), CXCL8(6-77), CXCL8(7-77), CXCL8(8-77) and CXCL8(9-77) in synovial fluid from a patient with RA. (C) Relative abundance of CXCL8 proteoforms in synovial fluids from RA and JIA patients (represented as mean ± SEM).

Article Snippet: After three washing steps, captured CXCL8 forms were detected using biotinylated polyclonal rabbit anti-human CXCL8 (500-P28BT; PeproTech, Rocky Hill, NJ), raised against recombinant human CXCL8(6-77), combined with peroxidase-conjugated streptavidine (R&D Systems, Minneapolis, MN).

Techniques: Mass Spectrometry, Activation Assay, Isolation, Liquid Chromatography with Mass Spectroscopy, Generated

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Kinetics of CXCL8 processing in the presence of synovial fluids from juvenile idiopathic arthritis patients. Exogenous CXCL8(1-77) was incubated with synovial fluids from JIA patients ( n = 4) for a period of 0, 1, 3, 6, 12 or 20 h. Total CXCL8 was extracted from synovial fluids by immunosorbent isolation and subjected to nano-LC-MS/MS analysis. For each sample, two nano-LC-MS/MS runs were performed to examine the presence of eight CXCL8 forms in MRM mode. (A) Extracted ion chromatograms (EIC) show the intensity of m/z values of signature fragment ions (±0.5) generated by fragmentation of a specific precursor ion (indicated between brackets) during protein elution. (B) Relative abundance of CXCL8 proteoforms in synovial fluids after 0, 1, 3, 6, 12, and 20 h of incubation (represented as mean ± SEM). (C) Pseudo-first order association kinetics of proteolytic modification of CXCL8(1-77) in the presence of synovial fluids (represented as mean ± SEM; n = 4).

Article Snippet: After three washing steps, captured CXCL8 forms were detected using biotinylated polyclonal rabbit anti-human CXCL8 (500-P28BT; PeproTech, Rocky Hill, NJ), raised against recombinant human CXCL8(6-77), combined with peroxidase-conjugated streptavidine (R&D Systems, Minneapolis, MN).

Techniques: Incubation, Isolation, Liquid Chromatography with Mass Spectroscopy, Generated, Modification

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Workflow for immunosorbent tandem mass spectrometry proteoform analysis (ISTAMPA). (1) Synovial fluids are collected from the inflamed joints of patients with arthritis. (2) Total CXCL8 is extracted from patient samples by immunosorbent purification using antibody-coupled magnetic beads. (3) Isolated CXCL8 proteoforms are subjected to analysis by nano-UPLC-MS/MS. (4, 5) The detection and quantification of signature fragment ions, generated by top-down collision-induced dissociation (CID) of a pre-selected precursor ion, at the expected elution time point, strongly indicates the presence of a specific CXCL8 proteoform. In general, truncated CXCL8 proteoforms display an enhanced capacity to induce neutrophil migration and activation. This figure is created with BioRender software.

Article Snippet: Polyclonal rabbit anti-human CXCL8 (60 μg/ml; vide supra ) was immobilized on a carboxyl sensor (Nicoya, Kitchener, ON, Canada) using an OpenSPR benchtop surface plasmon resonance (SPR) instrument (Nicoya).

Techniques: Mass Spectrometry, Purification, Magnetic Beads, Isolation, Tandem Mass Spectroscopy, Generated, Migration, Activation Assay, Software

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Detection of CXCL8 proteoforms by top-down tandem mass spectrometry. (A) Parameters are optimized to ensure that only the acid-labile Asp-Pro (DP) bond breaks during low-energy fragmentation and only two fragment ions are generated. (B) Mass spectra (single MS) showing the intensity of multiple charged ions of CXCL8(1-77), CXCL8(6-77) and CXCL8(9-77) as a function of their m/z values. Ions with m/z values of 892.8 [for CXCL8(1-77)], 932.3 [for CXCL8(6-77)] or 900.4 [for CXCL8(9-77)] were isolated and fragmented with low energy CID. The resulting fragmentation spectra are shown in the lower panels in (C) . Diamonds indicate the m/z value of the precursor ions selected for fragmentation. Extracted ion chromatograms (EIC) (top panels) show the detection of m/z values (±0.5) of the two signature fragment ions during protein elution. Relative quantification of CXCL8 forms is performed based on the intensity of the two major fragment ions in the EIC. (D) Dose-response curves for the simultaneous quantification of three CXCL8 forms in MRM mode (amounts ranging from 3.1 pg to 12.5 ng). Regression analysis was performed to fit curves to data. Results are represented as mean ± SEM ( n ≥ 4).

Article Snippet: Polyclonal rabbit anti-human CXCL8 (60 μg/ml; vide supra ) was immobilized on a carboxyl sensor (Nicoya, Kitchener, ON, Canada) using an OpenSPR benchtop surface plasmon resonance (SPR) instrument (Nicoya).

Techniques: Mass Spectrometry, Generated, Isolation

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Site-specific fragmentation of CXCL8 proteoform ions by top-down ion trap tandem mass spectrometry at limited fragmentation energy.

Article Snippet: Polyclonal rabbit anti-human CXCL8 (60 μg/ml; vide supra ) was immobilized on a carboxyl sensor (Nicoya, Kitchener, ON, Canada) using an OpenSPR benchtop surface plasmon resonance (SPR) instrument (Nicoya).

Techniques: Mass Spectrometry, Sequencing

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Detection of CXCL8 proteoforms in cell culture supernatant from osteosarcoma cells. The MG-63 osteosarcoma cell line was stimulated with the synthetic double stranded RNA poly rI:rC to produce CXCL8. Partially purified cell culture supernatant was subjected to top-down nano-LC-MS/MS analysis. Two nano-LC-MS/MS runs were performed to examine the presence and quantity of eight CXCL8 proteoforms in MRM mode. (A) Extracted ion chromatograms (EIC) showing the intensity of m/z values of signature fragment ions (±0.5) generated by fragmentation of a specific precursor ion (indicated between brackets) during protein elution. (B) Fragmentation spectra confirming the presence of signature ions of CXCL8(-2-77), CXCL8(1-77), CXCL8(3-77), CXCL8(6-77), CXCL8(7-77) and CXCL8(8-77). (C) Relative abundance of the detected CXCL8 proteoforms.

Article Snippet: Polyclonal rabbit anti-human CXCL8 (60 μg/ml; vide supra ) was immobilized on a carboxyl sensor (Nicoya, Kitchener, ON, Canada) using an OpenSPR benchtop surface plasmon resonance (SPR) instrument (Nicoya).

Techniques: Cell Culture, Purification, Liquid Chromatography with Mass Spectroscopy, Generated

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Detection of CXCL8 by top down-tandem mass spectrometry proves proteolytic activation in synovial fluids of arthritis patients. Total CXCL8 was extracted from synovial fluids of RA ( n = 14) and JIA patients ( n = 12) by immunosorbent isolation and subjected to nano-LC-MS/MS analysis. For each sample, two top-down nano-LC-MS/MS runs were performed to examine the presence of eight CXCL8 forms in MRM mode. (A) Extracted ion chromatograms (EIC) show the intensity of m/z values of signature fragment ions (±0.5) generated by fragmentation of a specific precursor ion (indicated between brackets) during protein elution. A representative experiment is shown (RA patient). (B) Representative fragmentation spectra confirm the presence of signature ions of CXCL8(1-77), CXCL8(6-77), CXCL8(7-77), CXCL8(8-77) and CXCL8(9-77) in synovial fluid from a patient with RA. (C) Relative abundance of CXCL8 proteoforms in synovial fluids from RA and JIA patients (represented as mean ± SEM).

Article Snippet: Polyclonal rabbit anti-human CXCL8 (60 μg/ml; vide supra ) was immobilized on a carboxyl sensor (Nicoya, Kitchener, ON, Canada) using an OpenSPR benchtop surface plasmon resonance (SPR) instrument (Nicoya).

Techniques: Mass Spectrometry, Activation Assay, Isolation, Liquid Chromatography with Mass Spectroscopy, Generated

Journal: Frontiers in Immunology

Article Title: From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8

doi: 10.3389/fimmu.2021.644725

Figure Lengend Snippet: Kinetics of CXCL8 processing in the presence of synovial fluids from juvenile idiopathic arthritis patients. Exogenous CXCL8(1-77) was incubated with synovial fluids from JIA patients ( n = 4) for a period of 0, 1, 3, 6, 12 or 20 h. Total CXCL8 was extracted from synovial fluids by immunosorbent isolation and subjected to nano-LC-MS/MS analysis. For each sample, two nano-LC-MS/MS runs were performed to examine the presence of eight CXCL8 forms in MRM mode. (A) Extracted ion chromatograms (EIC) show the intensity of m/z values of signature fragment ions (±0.5) generated by fragmentation of a specific precursor ion (indicated between brackets) during protein elution. (B) Relative abundance of CXCL8 proteoforms in synovial fluids after 0, 1, 3, 6, 12, and 20 h of incubation (represented as mean ± SEM). (C) Pseudo-first order association kinetics of proteolytic modification of CXCL8(1-77) in the presence of synovial fluids (represented as mean ± SEM; n = 4).

Article Snippet: Polyclonal rabbit anti-human CXCL8 (60 μg/ml; vide supra ) was immobilized on a carboxyl sensor (Nicoya, Kitchener, ON, Canada) using an OpenSPR benchtop surface plasmon resonance (SPR) instrument (Nicoya).

Techniques: Incubation, Isolation, Liquid Chromatography with Mass Spectroscopy, Generated, Modification